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Abstract
Background: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability (ID), as well as
the most frequent monogenic cause of autism spectrum disorder (ASD). Men with FXS exhibit ID, often associated
with autistics features, whereas women heterozygous for the full mutation are typically less severely affected; about
half have a normal or borderline intelligence quotient (IQ). Previous findings have shown a strong association
between ID and ASD in both men and women with FXS. We describe here the case of two sisters with ASD and
FXS but without ID. One of the sisters presented with high-functioning autism, the other one with pervasive
developmental disorder not otherwise specified and low normal IQ.
Methods: The methylation status of the mutated FMR1 alleles was examined by Southern blot and methylation-
sensitive polymerase chain reaction. The X-chromosome inactivation was determined by analyzing the methylation
status of the androgen receptor at Xq12.
Results: Both sisters carried a full mutation in the FMR1 gene, with complete methylation and random X
chromosome inactivation. We present the phenotype of the two sisters and other family members.
Conclusions: These findings suggest that autistic behaviors and cognitive impairment can manifest as independent
traits in FXS. Mutations in FMR1, known to cause syndromic autism, may also contribute to the etiology of high-
functioning, non-syndromic ASD, particularly in women. Thus, screening for FXS in patients with ASD should not be
limited to those with comorbid ID.
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Background
Fragile X syndrome (FXS) is caused by the expansion of
a CGG repeat in the 5′ untranslated region of the FMR1
gene located at Xq27.3 (for review see [1]). In its normal
form, FMR1 contains 5 to 55 CGG repeats. In the pres-
ence of over 200 repeats there is extensive methylation
of the CpG island in the gene’s promoter region, result-
ing in silencing of FMR1 expression. Premutation alleles
with 55 to 200 repeats are unstable and may expand to
full mutation alleles when transmitted maternally. Fra-
gile X mental retardation protein (FMRP), encoded by
FMR1, is an RNA-binding protein that travels from the
nucleus to the cytoplasm, where it regulates synaptic
and cytoskeleton-associated proteins [2]. In the absence
of FMRP, excessive and dysregulated mRNA translation
leads to altered synaptic function and loss of protein
synthesis-dependent plasticity [1]. FMRP can also regu-
late mRNA transport in dendrites and is important for
axonal guidance and formation of neural circuits.
The cognitive, behavioral and morphological manifes-
tations of FXS are highly variable [3]. Individuals with
FXS often display mild dysmorphic features, with long
face, prominent ears, arched palate and macroorchidism.
They can also exhibit a large spectrum of neuropsychi-
atric phenotypes, spanning from severe intellectual dis-
ability (ID) to mild learning problems or emotional
dysregulation, especially in heterozygous women [3].
Autistic behaviors, including impairments in social inter-
action, social anxiety, gaze avoidance, sensory hypersen-
sitivity, stereotypic movements and behaviors, poor
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motor coordination, delayed speech development and
echolalia, are also observed frequently in individuals
with FXS [4]. FXS is the most common monogenic cause
of autism spectrum disorders (ASD), identified in approxi-
mately 2% of cases [5,6]. Around 40% to 60% of male
and 20% of female patients with FXS meet criteria for
ASD [7-9]. Men with FXS often display both ID and aut-
istic features, with those exhibiting autistic traits being
more impaired [8-15]. In contrast, women are protected
by the normal allele on the second X chromosome and
usually exhibit a less severe phenotype. Although approxi-
mately 25% to 30% have ID (intelligence quotient (IQ)
< 70), women with FXS usually have an IQ in the border-
line to low normal range (75 to 90); most, however, exhibit
neurocognitive dysfunctions and anxiety as well as emo-
tional and attention deficits [16,17]. The variability of
FXS-related phenotype in women is influenced by the
level of residual FMRP expression and X inactivation
skewing. Skewing that favors the mutant allele increases
the clinical impairment, whereas skewing favoring the
normal allele decreases the likelihood of symptoms
[18,19]. In contrast with the frequent claim that cognitive
impairment accounts for the co-morbidity between FXS
and autism [13,20,21], here we describe the case of two sis-
ters, one with high-functioning autism and the other with
pervasive developmental disorder not otherwise specified
(PDD-NOS), both with low normal IQ. Both carried a full
mutation in the FMR1 gene with random X inactivation.
Methods
Laboratory investigations
Genomic DNA was isolated from blood lymphocytes. The
analysis of the FMR1 gene was performed using standard
methods: Southern blotting with EcoRI and Eag1 double di-
gest and the StB12.3 probe, direct amplification of the
CGG-repeat using flanking primers, and methylation-
sensitive PCR after bisulphite treatment of DNA. The X-
chromosome inactivation ratio was determined by analyz-
ing the methylation status of the androgen receptor (AR)
locus at Xq12, as previously described [22]. The X-
inactivation ratio ranges from 50:50 (random inactivation)
to 100:0 (complete non-random inactivation). X inactiva-
tion was considered skewed if the ratio was over 80:20.
To further delineate the contribution of rare genomic
variants to the clinical phenotype, we genotyped the index
case by using the Illumina Infinium 1 M single nucleotide
polymorphism microarray (Illumina Inc, San Diego, CA).
We used two copy number variation (CNV) calling
algorithms, QuantiSNP and PennCNV, and the CNV
viewer SnipPeep (http://snippeep.sourceforge.net/). To ob-
tain high-confidence calls, the CNVs identified were vali-
dated by visual inspection of the Log R ratio and B allele
frequency values. Criteria for detecting rare CNVs have
been described previously [23].
Ethical statement
This study was approved by the local institutional review
board (Comité de Protection des Personnes Île-de-France
VI, Hôpital Pitié-Salpêtrière). Written informed consent
was obtained from all participants of the study, signed by
the patients, the parents or the legal representatives.
Results
Clinical reports
Patient 1: Thirty year-old female, referred to our clinic for
assessment of high-functioning ASD. She is the first child
of healthy non-consanguineous Caucasian parents. Preg-
nancy and delivery were normal. She was born at gesta-
tional week 39, and her weight (3,900 g), length (50 cm)
and head circumference (35 cm) were in the normal range.
Early development was considered normal despite moder-
ate sleep difficulties and delay in walking (18 months). Her
first words occurred before 24 months, but her parents
reported an apparent stagnation of her development. When
she started school at three years of age, her language was
poorly developed and stereotyped. Teachers mentioned that
she was isolated, lacked social reciprocity and had major
misunderstandings of social cues. She had a small reper-
toire of facial expressions and limited use of gestures to
communicate. She also exhibited various stereotyped beha-
viors associated with restricted interests. Despite her diffi-
culty to integrate at school, she acquired normal writing
and reading skills, and attended a normal school until
15 years of age. At this time, unable to follow a professional
formation, she integrated a psychiatric day care two days
per week for 9 years, and now remains at home. When re-
ferred to our center at the age of 30, she received a diagno-
sis of high-functioning autism based on Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-
IV) and International Statistical Classification of Diseases
and Related Health Problems, 10th Revision (ICD-10) cri-
teria. Assessment of ASD was performed using the Autism
Diagnostic Interview-Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS); she met criteria
for autism on both instruments (Table 1). Her IQ, mea-
sured with the Wechsler Adult Intelligence Scale (WAIS),
was in the low normal range, with a full scale IQ of 85.
Comorbid Axis I mental disorders were evaluated with the
Diagnostic Interview for Genetic Studies (DIGS). The pa-
tient had no specific associated disorders, but fulfilled
DSM-IV criteria for chronic motor tics. At examination,
she had a long face, with a high forehead and normal ears.
Her general and neurological examination was normal, with
mild generalized obesity (body mass index 31, height
1.59 m, weight 78.4 kg). She had generalized hirsutism,
related to a partial 21-hydroxylase deficiency discovered
during late childhood. She had increased levels of 17-
hydroxyprogesterone and adrenal androgens; molecular
genetic testing was not performed.
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Patient 2: Twenty-eight-year-old female at the time of
assessment, born at full-term after an uneventful preg-
nancy. Her motor and language milestones were normal.
She integrated school early, but showed major difficulties
in social interactions. She was isolated despite being inter-
ested in others. Similar to her sister, teachers mentioned
difficulties in her relationships with schoolmates. At that
time, parents and teachers considered that she only had
symptoms of social avoidance. Despite a weakness in re-
ceptive and expressive language, she pursued a normal
education until 18 years of age. She completed a profes-
sional formation and obtained a degree in childcare. She
worked at different nurseries for short periods of time, but
was unable to keep her job.
After the diagnosis of FXS and ASD in her sister, she
was referred to our hospital for a clinical evaluation. Her
prosody was normal, but her vocabulary was clearly lim-
ited. Direct eye gaze was rare and interaction difficult to
establish. The clinical evaluation revealed that she had
PDD-NOS. She did not reach cut-off for autism on the
ADI-R, but met criteria for autism on the ADOS (Table 1).
Evaluation with the WAIS-III showed a verbal IQ of 81
and a non-verbal IQ of 96. The patient had a lifetime his-
tory of panic disorder without agoraphobia. However, this
diagnosis remained uncertain because a few months later,
hyperthyroidism was discovered and treated, which
resulted in remission of the panic disorder. Unlike her
sister, she did not have a medical history of congenital ad-
renal hyperplasia. At examination, she had no dysmorphic
features. Her general and neurological examination was
normal except for mild generalized obesity (body mass
index 32, height 1.59 m, weight 81.3 kg).
Other members of the pedigree (Figure 1): A younger
brother was reportedly healthy. The father did not report
any personal or familial medical or psychiatric history. His
clinical examination at the age of 58 years was within nor-
mal limits. The mother had no specific medical history,
with the exception of panic disorder associated with
agoraphobia from the age of 20 years. She did not report
any sign of premature ovarian failure. When evaluated at
the age of 57 years, her clinical examination was normal
and she had a normal intelligence (WAIS III: verbal IQ
104, non verbal IQ 117, full scale IQ 110). Her father, who
died at 85 years of age, had been hospitalized for dementia
and ataxia. Clinical reports mentioned that he showed
spasticity, tremor and rigidity as well as severe cognitive
impairment, with onset around 75 years of age. The diag-
nosis of FXS in his granddaughter led to the re-
assessment of his medical records and he was diagnosed
retrospectively with fragile X-associated tremor/ataxia
syndrome (FXTAS), which affects carriers, principally
men, of premutation alleles of the FMR1 gene. A review
of brain biopsies obtained during autopsy revealed lesions
typical of FXTAS, combining a few eosinophilic nuclear
inclusions in the hippocampus and near the pons, affect-
ing both neurons and glia, and enlarged inclusion-bearing
astrocytes. In addition, neuropathological findings charac-
teristic of Parkinson’s disease were observed in the locus
Table 1 Autism Diagnostic Interview-Revised and
Autism Diagnostic Observation Schedule scores in Patients
1 and 2
Patient 1 Patient 2
ADI-R
Age at evaluation (y) 30 28
Social (cut-off = 10) 20 11
Verbal communication (cut-off = 8) 17 4
Repetitive behavior (cut-off = 3) 6 1
Abnormality prior to 36 months (cut-off = 1) 3 1
ADI-R diagnosis autism not autism
ADOS (module 4)
Age at evaluation (y) 33 yes 28
Communication (cut-off autism= 3, ASD= 2) 6 4
Social interaction (cut-off autism= 6, ASD= 4) 14 6
Total communication + social
(cut-off autism= 10,ASD= 7)
20 10
Imagination 3 0
Restricted behaviors and interests 8 0
ADOS diagnosis autism autism
Final research diagnosis autism PDD NOS
ADI-R Autism Diagnostic Interview-Revised, ADOS Autism Diagnostic
Observation Schedule, ASD autism spectrum disorder, PDD-NOS pervasive
developmental disorder not otherwise specified.
Figure 1 Pedigree of the two affected sisters (black circles)
with fragile X syndrome and high functioning autism spectrum
disorder. The mother and the paternal grandfather carried the
premutation (black dots). The grandfather had fragile X associated
tremor/ataxia syndrome (grey square). The black diamond indicates
a miscarriage of indeterminate gender.
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coeruleus and substantia nigra. Numerous neurofibrillary
tangles in the hippocampus and neuritic plaques in the
isocortex suggested an associated Alzheimer disease,
Braak stage 5.
Analysis of the FMR1 gene and X inactivation
Southern blot analysis of the CGG expansion at FMR1
revealed a full mutation in both patients, with about 450
CGG repeats in the proband and 370 CGG repeats in her
sister. Both mutated alleles were associated with complete
methylation based on the Southern blot profile. The sec-
ond allele was normal in the two sisters, with 29 repeats.
The asymptomatic mother carried a premutated allele (93
repeats), as did the mother's father (100 repeats). In
addition, no rare CNVs were detected in Patient 1, either
on the X chromosome or the autosomes.
We hypothesized that the lack of intellectual deficit in
the sisters could be linked to a skewed X inactivation in
favor of the non-mutated allele. However, the X inactiva-
tion profile, assessed at the AR locus, was normal in the
proband (45:55), her sister (47:53) and the mother
(45:55).
Discussion
Women who are heterozygous for the full FMR1 mutation
are less cognitively impaired than men, with about one-
third presenting with ID and the rest exhibiting IQs in the
borderline to low normal range [11,16,17]. Although the
majority of women with FXS are not intellectually dis-
abled, they often manifest a wide range of psychiatric and
cognitive impairments, including anxious disorders, atten-
tion deficit-hyperactivity disorders, ASD and executive
deficits [24,25]. In women as well as in men with FXS, the
literature reports a strong association between ID and aut-
istic features, with individuals with a lower IQ being more
likely to be diagnosed with autism [8-10,12,14,15,20,26]. A
negative correlation between IQ scores and the intensity
of autistic symptoms, as measured with the ADOS, was
observed in men and women [13,15]. The level of cogni-
tive impairment is a major predictor of autistic behavior in
FXS, stronger than FMRP levels in lymphocytes [13,27].
These findings would seem to support the suggestion that
the occurrence of autistic features in individuals with gen-
etic syndromes and ID is largely the consequence of the
cognitive deficit, which decreases their compensatory cap-
acity [28]. Here, we describe the case of two sisters carry-
ing a full mutation of FMR1 with high-functioning ASD,
suggesting that autistic features can emerge independently
from ID, at least in women. It should be noted, however,
that both our patients have an IQ that is low relative to
estimates based on familial intelligence, as shown previ-
ously in women with FXS [29]. In agreement with our
findings, a previous study found a lack of correlation be-
tween autistic behaviors and IQ among girls with FXS
[30]. Thus, fragile X mutations can manifest in a wide var-
iety of clinical diagnoses crossing categorical boundaries,
specifically ID and ASD. The mechanisms involved in the
determinism of specific trajectories remain to be eluci-
dated and could be influenced by genetic, epigenetic and
environmental processes [26].
The prevalence of women with high-functioning ASD
and FXS is probably underestimated because FXS testing is
not systematically included in the etiological screening of
patients with high-functioning ASD. In the absence of a
family history of ID, premature ovarian failure or Parkin-
sonism, the search for FMR1 abnormalities is usually not
recommended in patients with high-functioning ASD
(American Academy of Pediatrics, [31]). Shyness or social
anxiety, commonly mentioned in studies of women with
FXS, could be, at least in some cases, misinterpretations of
symptoms belonging to the autism spectrum. Also, mild
manifestations of ASD are not evaluated or are misevalu-
ated in most reports by the use of inadequate clinical
instruments to explore social and communicative deficits
in patients with FXS. Thus, if ASD were indeed underesti-
mated in high-functioning patients with FXS, one could
suggest that ID and ASD could be phenotypic variants,
spanning from ID without ASD to ASD without ID. Specif-
ically in women with FXS, the significant heterogeneity
reported for cognitive impairment ranging from severely
impaired to normal IQ, or even high IQ in rare cases [32],
could also be true for autistic symptoms, with some indivi-
duals presenting independence between both dimensions,
as shown for many other genetic disorders implicated in
the etiology of ASD [33]. In particular, many X-linked ID
genes have been associated with a profound phenotypic
heterogeneity and can be disrupted in individuals without
ID. For example, NLGN4X mutations are involved in a
wide spectrum of phenotypes, ranging from mild isolated
ID without communication deficits to Asperger syndrome
with normal intelligence (for review see [34]).
The phenotypic severity of full mutations in women is
widely assumed to be determined by X inactivation [18,19].
However, in our patients, the proportion of active normal
alleles was approximately at equilibrium (0.55) in both
cases. This contrasts with previous findings, in which
women who are phenotypically normal have a skewed X
inactivation pattern in favor of the inactive X carrying the
mutation [18,19]. Additional mechanisms may underlie the
variable expressivity observed in FXS. First, the individual
genetic background may modulate the FXS phenotype. In
our proband, however, the search for rare CNVs did not
reveal mutations in other genes that could explain the de-
velopment of autistic features independently of ID. Second,
variations in the FMRP level resulting from mosaicism of
the FMR1 repeat expansion or incomplete FMR1 promoter
methylation [13,35] can also impact the phenotypic vari-
ability observed in patients. For example, there are several
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reports of male patients with FXS with learning disability
but not ID, with partial FMRP expression arising from
transcription of unmethylated alleles [35], including a male
with Asperger syndrome [36]. In the sisters reported here,
the mutated alleles were fully methylated. Finally, the par-
tial block in 21-dehydrogenase reported in Patient 1 could
potentially explain why she was more severely affected than
her younger sister. Girls with congenital adrenal hyperpla-
sia have more autistic traits than their unaffected sisters,
suggesting that prenatal exposure to high levels of testos-
terone increases the vulnerability to ASD [37].
Conclusions
Our report highlights the necessity for further investigation
of the association between ASD and FXS in larger samples
of high-functioning female individuals with ASD, which
could contribute to the understanding of the complexity of
the relationship between ID and ASD. In FXS as well as in
many other genetic disorders, patients have been shown to
exhibit autistic symptoms spanning from mild to severe,
associated or not with ID [33]. This report stresses the im-
portance of clinicians being aware of the association be-
tween a full mutation of FMR1 and high-functioning ASD
in women and, vice versa, the importance of a careful psy-
chiatric examination of women with FXS.
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